PA
LEGN icon

Parallel Advisors’s Legend Biotech LEGN Stock Holding History

Parallel Advisors’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.7K Buy
2,084
+1,323
+174% +$25.2K ﹤0.01% 2155
2025
Q4 		$16.5K Sell
761
-286
-27% -$8.19K ﹤0.01% 2388
2025
Q3 		$34.1K Buy
1,047
+662
+172% +$24.4K ﹤0.01% 1987
2025
Q2 		$13.7K Buy
385
+2
+0.5% +$65 ﹤0.01% 2359
2025
Q1 		$13K Sell
383
-1,699
-82% -$60.9K ﹤0.01% 2333
2024
Q4 		$67.7K Buy
+2,082
New +$86.2K ﹤0.01% 1472

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FBIL
First Beijing Investment Ltd Hong Kong $2.32B AUM 8.06% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Parallel Advisors's LEGN Position: Q1 2026 in Review

Parallel Advisors increased its Legend Biotech (LEGN) stake by 174% in Q1 2026, buying an estimated $25.2K and bringing the position to 2,084 shares worth $37.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2155.

Parallel Advisors first reported a position in LEGN in Q4 2024 and has held it in 6 quarters since. The position peaked at $67.7K in Q4 2024. 189 funds tracked by Wall St. Rank hold LEGN as of Q1 2026.

  • Parallel Advisors held 2,084 shares of Legend Biotech worth $37.7K as of Q1 2026.
  • Parallel Advisors bought 1,323 Legend Biotech shares in Q1 2026, an estimated $25.2K.
  • Legend Biotech made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2155 holding.
  • Parallel Advisors first reported a position in Legend Biotech in Q4 2024 and has held it in 6 quarters since.
  • Parallel Advisors's Legend Biotech position peaked at $67.7K in Q4 2024.
  • 189 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.